CURRICULUM VITAE WITH TRACK RECORD Øyvind Sverre Bruland



PERSONAL INFORMATION
Family name, First name: Bruland, Øyvind Sverre
Date of birth: *14.12.1952*
Sex: Male
Nationality: Norwegian
Researcher unique identifier: orcid.org/0000-0003-1631-3733
URL for personal web site: www.bruland.info

EDUCATION

1989	Dr. Med. (**Ph.D.**): **Disputation date:** *15.01.1989.* *Faculty of Medicine*, University of Oslo, Norway
1979	Cand. Med. (**M.D.**) *Faculty of Medicine*, University of Oslo, Norway
1971-1976	Cand.Mag. (**Bachelor of Science**), Studies in Chemistry, Mathematics, Biology and Zoology, University of Trondheim and University of Oslo, Norway

CURRENT AND PREVIOUS POSITIONS

2008-present	Professor of Clinical Oncology (Tenure & main position), University of Oslo, Norway
2004-present	Senior Consultant Oncologist, Department of Oncology (part time position), The Norwegian Radium Hospital, Oslo University Hospital, Norway
2005-2013	Professor of Comparative Oncology (adjunct position), The Norwegian School of Veterinary Medicine, Oslo, Norway
2003-2006	Head of Clinical Research, Center for Research & Training in Radiation Oncology, Norway
2002-2008	Professor II in Clinical Oncology, University of Oslo, Norway
1999-2002	Professor II in Clinical Oncology, University of Tromsø, Norway
1996-2004	Sect. Head & Consult, Oncologist, Dept. of Oncology, Norwegian Radium Hospital, Norway

AWARDS

1992 –	Granted “The Kreyberg Award” in Experimental Pathology, University of Oslo, Norway
2014 –	Granted “The Innovation Price”, University of Oslo; shared with Roy H Larsen

MOBILITY (*research stays abroad lasting more than three months*)

2004.01-2004.05	Visiting Professor, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, USA

SUPERVISION OF GRADUATE STUDENTS AND RESEARCH FELLOWS

1994-present	Main supervisor or co-supervisor for 24 candidates having completed their theses. Supervisor in 4 ongoing PhD projects. University of Oslo, Norway

TEACHING ACTIVITIES

2007 – 2019	Responsible for the compulsory one week course in “Practical Radiotherapy” for all residents in oncology, Oslo University Hospital, Oslo, Norway
2008 – present	Various lectures, clinics and clinical examination course for medical students, Faculty of medicine, University of Oslo, Norway

INSTITUTIONAL RESPONSIBILITIES

2012 – 2019	Head *“Sarcoma Research”,* Cancer Clinic, Oslo University Hospital, Norway

COMMISSIONS OF TRUST
On the “Editorial Board” of three scientific international journals

ORGANISATION OF SCIENTIFIC MEETINGS

1992	Organizer and chairman, International Workshop: Comparative Osteosarcoma Research, Oslo/Eidsbugarden
1997	Organizer and chairman, Scandinavian Symposium in Radiation Oncology, Rosendal
2002	Scientific Chairman, 18th.UICC International Cancer Congress, Oslo
2003	Organizer and chairman, Targeted Cancer Therapies – An Odyssey, Tromsø

MEMBERSHIPS OF SCIENTIFIC SOCIETIES (if applicable)

2008 - present Elected member of The Norwegian Academy of Science and Letters – Det Norske Videnskaps-Akademi

2021 – present Groups Leader, Medical Sciences, The Norwegian Academy of Science and Letters

TRACK RECORD

Publications last 10 years: 97

Publications in total: 252 papers. For a complete list see www.bruland.info

H-Index: 42. **Citations: 8367** (without self-citations). Source: ISI Web of Science, January 2022.

Ten publications from the last ten years with the highest number of their citations:

1. C. Parker, S. Nilsson, *et al.* Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med* 2013; 369: 213-223. *Citations: 1893*.
2. O. Sartor, R. Coleman, *et al.* Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. *Lancet Oncol* 2014; 15: 738-746. *Citations: 320*.
3. S. Nilsson, P. Strang, *et al.* A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. *Eur J Cancer* 2012; 48: 678-686. *Citations: 177*.
4. S. Nilsson, S. Franzen*, et al.* Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases. *Clin Genitourin Cancer* 2013; 11:20-26. *Citations: 87.*
5. K. Berner T. B. Johannesen, *et al.* Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma. *Acta Oncol* 2015; 54:25-33. *Citations: 74.*
6. N. Abbas, H. Heyerdahl, *et al*. Experimental alpha-particle radioimmunotherapy of breast cancer using Th-227-labeled p-benzyl-DOTA-trastuzumab. *EJNMMI Res* 2011; 1:18. *Citations: 41.*
7. S. Smeland, Ø. S. Bruland, *et al*. Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma 63 patients with a minimum follow-up of 4 years. *Acta Orthop* 2011; 82:211-216. *Citations: 38.*
8. C. Parker, C. Christoper, *et al.* Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. *Eur Urol* 2018; 73: 427-435. *Citations: 33*.
9. O. Sartor, P. Hoskin, Ø. S. Bruland. Targeted radio-nuclide therapy of skeletal metastases. *Cancer Treat Rev* 2013: 39: 18-26. *Citations: 30.*
10. V. Stenberg, A. Juzeniene, Q. Chen, X. Yang, Ø. Bruland, R. Larsen*.* Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [^{212}Pb]Pb-NG001 for prostate cancer*. J Labelled Comp Radiopharm* 2020; 63:129-143. *Citations: 15*.

Granted patents:

- Bruland holds six international patents related to targeted radionuclide therapies.
- US 2014235924 A1 “Method of radiotherapy” by Larsen RH, **Bruland ØS** (f2014)
- US 2004009955 A1 “Method of prophylaxis” by Larsen RH, **Bruland ØS** (f2004)
- US 6635234 B1 “Administering bone seeking alpha-emitting radionuclide having half-life allowing deeper incorporation into matrix of bone surfaces before decay and radioactive decay products from its transformation do not translocalize significantly” by Larsen RH, Henriksen G, **Bruland ØS** (f2000, g2003)
- EP 1617876 B1 “Thorium-227 for use in radiotherapy of soft tissue disease” by Larsen RH and **Bruland ØS** (f2004, g2014)
- US 8628749 B2 “Radioimmunoconjugates and uses thereof” by Larsen RH, Dahle J, **Bruland ØS** (f2011, g2014)
- US 6635234 B1 “Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning” by Larsen RH, Henriksen G, **Bruland ØS** (f1999, g2003)

FOUNDER

1997 - Co-founder of Algeta ASA together with Roy H. Larsen. The product Alpharadin (Radium-223), currently marketed by Bayer as Xofigo, was approved by FDA & EMA in 2013 for patients with skeletal metastases from prostate cancer. Phase-2 clinical studies in breast cancer are ongoing.

2009 – Co-founder of Nordic Nanovectors A/S Oslo

2010 – Co-founder of Oncoinvent A/S, Oslo

2018 – Co-founder of Nucligen A/S, Oslo